Where to Find Your Weight From When GLP-1 Was First Prescribed

Why Your Baseline Weight Is More Useful Than You Might Think

Your starting weight is not just a number from the past. It is the clinical anchor for everything that follows on GLP-1 therapy. Prescribers use it to assess whether you are responding adequately, insurers use it to verify medical necessity, and you can use it to see an accurate percentage of body weight lost, which is the metric that predicts health outcomes, not the raw pounds on the scale today.

Semaglutide trials report outcomes in percent body weight loss, not absolute pounds. If you do not know where you started, you cannot calculate that figure yourself. The STEP 1 trial enrolled 1,961 adults (roughly 75% women) and found a mean body weight reduction of 14.9% over 68 weeks with semaglutide 2.4 mg weekly. Without your own baseline, a 20-lb loss could represent 10% or 18% of starting weight, two very different clinical pictures.

Why Women Specifically Need to Track This

Women's weight fluctuates across the menstrual cycle by 2 to 5 lb on average due to fluid retention driven by estrogen and progesterone shifts. That means the number on any random Tuesday is not your true weight. Your baseline from a clinic visit is a standardized, clothed or semi-clothed, time-of-day-documented measurement that is far more reliable than a home scale reading.

Perimenopausal women face an added complication: weight tends to increase by 1.5 kg over the menopausal transition independent of caloric intake, and fat redistributes toward the abdomen. If your GLP-1 was prescribed during perimenopause, your baseline captures a hormonally distinct moment in your metabolic history. That context matters when you and your clinician interpret your response.

Women with PCOS also carry a specific burden here. Insulin resistance in PCOS can blunt GLP-1 response compared to weight-matched women without PCOS, so tracking percent weight lost against a documented baseline helps identify whether titration or adjunct therapy is warranted.

The Fastest Place to Look: Your Patient Portal

Most women using a GLP-1 prescribed in the last five years will find their baseline weight inside a patient portal in under three minutes. This is the quickest path.

Epic MyChart (and MyChart-Powered Portals)

Epic MyChart is the most widely used portal in the United States. Log in and follow this path:

1. Select Health from the top navigation.
2. Choose Health Summary or Vitals.
3. Filter or scroll to the date of your first GLP-1 prescription.
4. Your weight, height, BMI, and blood pressure from that visit will appear.

If your clinic uses Epic, the prescribing visit note will also be available under Health > Visit Summaries, and the note will list your weight as a vital sign at the top.

Athena Health, FollowMyHealth, and Other Portals

Athena-based portals label this section My Health > Vitals or Past Visits. FollowMyHealth uses My Record > Vitals. The logic is the same across all major platforms: find the visit date, find the vitals recorded that day. The date of your first prescription will match either the date your provider placed the order or the date of the in-person or telehealth intake visit.

Telehealth-Specific Portals

If you started GLP-1 through a telehealth platform (including WomanRx), your intake form recorded your self-reported weight. That number lives in your care plan or intake summary. At WomanRx, you can find it under My Care Plan > Treatment History. Self-reported weight is slightly less precise than a clinic scale, but it is the number your prescriber used to calculate your starting BMI and confirm eligibility, so it is the appropriate clinical baseline for your treatment.

Secondary Sources When the Portal Does Not Have It

If you cannot access your portal, it is unavailable, or the data is simply missing, several backup sources reliably carry your weight from the prescribing visit.

The Visit Note or Superbill

Every clinical encounter generates a visit note, and the first line of every note's objective section is the vital signs. Call or message the prescribing clinic and request a copy of the visit note or the superbill (the billing document) from the date GLP-1 was ordered. Both list weight. Under HIPAA 45 CFR §164.524, you are entitled to a copy of your medical record, typically within 30 days.

Your Pharmacy Records

When a GLP-1 was first dispensed, the pharmacy recorded the dispensing date. Cross-referencing that date with your clinic's visit records narrows down the right encounter. Your pharmacy may not have your weight, but the fill date helps you identify which visit note to request.

Insurance Explanation of Benefits (EOB)

Your insurer's EOB documents every covered service by date and diagnosis code. If your GLP-1 was covered or partially covered, the EOB will list the service date. Log into your insurer's member portal, search claims for the GLP-1 drug name (semaglutide, tirzepatide, liraglutide), and note the service date. Then use that date to pull the visit note from your provider.

Lab Results from the Same Date

Many prescribers order baseline labs alongside a GLP-1 prescription: fasting glucose, HbA1c, a lipid panel, or thyroid function. ADA Standards of Care recommend baseline metabolic assessment before initiating obesity pharmacotherapy. Those lab orders are time-stamped. If you can find a lab result from around your start date, the ordering date on the lab requisition or portal entry pinpoints the visit.

What to Do If Records Are Truly Unavailable

Occasionally records are missing. The clinic closed, the portal purged data, or you switched providers. Here is a practical sequence.

Step 1: Check Your Phone or Email

Many telehealth platforms email a visit summary automatically. Search your inbox for the prescriber's name, the drug name (Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda), or the word "prescription." A weight is often embedded in that email summary.

Step 2: Check Your Own Records

Did you weigh yourself the morning of your first injection? Check your Apple Health, Google Fit, Fitbit, or Oura app for a weight reading around that date. These apps log weight entries with timestamps. A home scale reading from the start week is not identical to a clinical weight, but it is a defensible personal baseline.

Step 3: Estimate From Your BMI

If your prescribing note listed your BMI and height, you can back-calculate your weight. BMI = weight (kg) divided by height (m) squared. Solve for weight: weight = BMI x height (m) squared. Convert to pounds by multiplying kilograms by 2.205. This is algebraically exact as long as BMI and height are correct.

Step 4: Use a Surrogate Anchor

If none of the above works, identify the earliest weight you can document and note how many weeks into therapy it was. Your prescriber can use standard GLP-1 titration response curves to back-estimate where you likely started. This is an approximation, not a true baseline, but it is enough for clinical decision-making.

The WomanRx Baseline Recovery Framework (for women who cannot locate their starting weight):

| Step | Action | Expected Outcome | |------|--------|-----------------| | 1 | Search email for visit summary | Finds weight in 60% of telehealth cases | | 2 | Check health-tracking app for start-week weight | Provides personal baseline within 1-2 lb | | 3 | Back-calculate from documented BMI and height | Algebraically exact if both values are available | | 4 | Request pharmacy fill date, then pull visit note | Identifies the correct encounter in clinic records | | 5 | Clinician estimation using titration curves | Approximation only; document as estimated |

How to Interpret Your Baseline Weight as a Woman

Finding the number is only step one. Understanding it in context is what makes it clinically useful.

Percent Body Weight Lost: The Right Metric

Raw pounds lost is emotionally satisfying but clinically incomplete. Percent body weight lost is what the major GLP-1 trials use, what the Endocrine Society's obesity pharmacotherapy guidelines reference, and what your prescriber uses to decide whether you are an adequate responder. An adequate response is generally defined as at least 5% body weight loss at 12-16 weeks at the therapeutic dose.

To calculate: subtract your current weight from your baseline weight, divide by your baseline weight, multiply by 100. Keep a note of this number each time you reach a new milestone.

Accounting for Hormonal Fluctuations

If you are premenopausal, weigh yourself on the same cycle day each month when tracking progress, ideally day 2 or 3 of your period when fluid retention is lowest. This reduces noise in your trend line. The 2-5 lb cyclical variation documented in hormonal fluid retention research can otherwise make it look like you lost or gained weight when you simply shifted from day 14 to day 27 of your cycle.

Postmenopausal women do not have this cyclical issue but may see more day-to-day sodium-driven variation. Weigh yourself on the same day of the week, same time of morning, before eating or drinking.

PCOS, Insulin Resistance, and Slower Response

Women with PCOS who also have significant insulin resistance may lose weight more slowly in the first 8-12 weeks of GLP-1 therapy than women without PCOS. A 2023 systematic review in Fertility and Sterility found that GLP-1 receptor agonists reduced body weight in women with PCOS by a mean of 5.3 kg, with concurrent improvements in androgen levels and menstrual regularity. If your baseline weight is documented and your early response looks slower than expected, that data point should prompt a conversation about insulin-sensitizing adjuncts (metformin, inositol) rather than premature discontinuation.

Pregnancy, Lactation, and Contraception: What You Need to Know

GLP-1 receptor agonists are contraindicated in pregnancy. This is not a theoretical caution. Animal studies showed fetal harm at clinically relevant exposures, and FDA labeling for semaglutide states that women of reproductive potential should use effective contraception during therapy and for at least two months after stopping, given the drug's half-life.

If You Become Pregnant While on a GLP-1

Stop the medication immediately and contact your OB or prescriber. Your baseline weight will become relevant to your obstetric team because weight gain targets in pregnancy are calculated from your pre-pregnancy weight. ACOG guidelines recommend total gestational weight gain of 11-20 lb for women with obesity (BMI >30 at conception). Your GLP-1 baseline weight is effectively your pre-pregnancy weight if conception occurred during therapy.

Lactation

GLP-1 receptor agonists have not been studied in breastfeeding women. The molecular weight of semaglutide is high (approximately 4,114 Da), which suggests limited transfer into breast milk, but there are no human lactation pharmacokinetics data. LactMed lists semaglutide as having insufficient data to assess safety. The general clinical recommendation is to hold GLP-1 therapy during breastfeeding and resume after weaning.

Contraception Considerations

Oral contraceptives (OCPs) may have slightly reduced absorption when GLP-1 therapy significantly slows gastric emptying. Women relying on OCPs for contraception during GLP-1 therapy should discuss this with their prescriber. Tirzepatide's prescribing information specifically notes that non-oral contraceptives may be preferable, or that a barrier method should be added for four weeks after each OCP dose change during the titration phase. Semaglutide's label includes a similar note. Using a long-acting reversible contraceptive (IUD or implant) removes this pharmacokinetic concern entirely.

Who Needs Their Baseline Weight Most Urgently

Not every woman on a GLP-1 needs to spend significant time recovering this number. But certain situations make it genuinely time-sensitive.

Prior Authorization Renewal

Commercial insurance and many GLP-1 coverage programs require annual or semi-annual documentation of ongoing response. Response is usually defined as >5% weight loss from baseline. CMS prior authorization processes for anti-obesity medications increasingly require documented baseline weight. If your insurer asks for a letter of medical necessity, your prescriber will need your starting weight.

Hitting a Plateau

If your weight loss has stalled, your prescriber needs to know how much you have already lost to decide whether to titrate the dose, switch agents, or add a behavioral or metabolic adjunct. Without a baseline, the plateau cannot be contextualized.

Transitioning Providers

If you are moving from a primary care provider to a weight-management specialist, or from one telehealth platform to another, bringing your documented baseline weight is the single most useful piece of information after your current medication and dose.

Trying to Conceive After GLP-1 Therapy

If you lose significant weight on a GLP-1 and then stop to attempt pregnancy, your OB will want to know your pre-treatment weight, your lowest weight on treatment, and your weight at discontinuation. All three numbers together give the clearest picture of your body composition history for obstetric risk calculation.

Keeping Records Going Forward

Once you have recovered your baseline weight, build a simple system so you never have this problem again.

Keep a private note in your phone with: the date GLP-1 was started, the drug and starting dose, your weight that day, your height, and your calculated BMI. Update it each time your dose changes. Take a screenshot of your portal vitals each time you have a clinic visit. If you use a telehealth service, download the care plan PDF after each check-in.

The American Heart Association's guidance on obesity management explicitly recommends that patients maintain their own longitudinal weight record, particularly when treatment involves pharmacotherapy, because care transitions are common and records are not always transferred. A woman managing her own health data is not doing her provider's job. She is protecting her own continuity of care.

As one endocrinologist on the Endocrine Society's obesity task force stated in the 2022 clinical practice guideline: "Obesity pharmacotherapy decisions should be based on objective response data from a documented baseline, not patient recall." Your baseline weight is that objective anchor.

A final practical note: if you started GLP-1 therapy more than five years ago, request your records sooner rather than later. HIPAA requires most covered entities to retain records for six years from creation, but clinic closures and practice acquisitions can complicate access. The request costs nothing and takes five minutes.